- Market Capitalization, $K 14,197,828
- Shares Outstanding, K 54,820
- Annual Sales, $ 375,370 K
- Annual Income, $ -34,550 K
- 60-Month Beta 1.57
- Price/Sales 14.63
- Price/Cash Flow N/A
- Price/Book 5.00
|Period||Period Low||Period High||Performance|
| || |
+36.34 (+15.96%)since 01/17/20
| || |
+75.55 (+40.08%)since 11/18/19
| || |
+160.91 (+156.04%)since 02/15/19
Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Mechelen, Belgium; 29 January 2020, 8.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces today that the US Food & Drug Administration (FDA) and the European Commission (EC) have granted investigational...
Galapagos is preparing to deliver its first medicine to patients
Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on...
Mechelen, Belgium; 13 January 2020, 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) has completed recruitment for the PINTA Phase 2 clinical trial with oral GPR84 inhibitor GLPG1205.
Mechelen, Belgium; 9 January 2020; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc.
Mechelen, Belgium; 9 January 2020, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 38th Annual J.P. Morgan Healthcare Conference on January 14-16, 2020.
Gilead Sciences (GILD) collaborates with Eisai for the distribution and co-promotion of its rheumatoid arthritis candidate, filgotinib. The companies will jointly commercialize the drug, if approved.
Gilead (GILD) files an NDA for filgotinib with the FDA for the treatment of adults with moderate-to-severe rheumatoid arthritis.
|DWA Developed Markets Momentum Invesco ETF|
|S&P Intl Developed Quality Invesco ETF|
|S&P Intl Developed Momentum Invesco ETF|
|Europe ETF FTSE Vanguard|
|FTSE RAFI Dev Markets Ex-U.S. Small-Mid Invesco|